Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals reported positive late-stage trial data for its sleep disorder therapy Hetlioz, also known as tasimelteon, in adults with delayed sleep-wake phase disorder, setting up another label expansion for the FDA-approved sedative. The company said it plans to submit a supplemental New Drug Application, which, if approved, could make the drug the first FDA-approved medicine for DSWPD, a condition characterized by the inability to fall asleep until the early morning hours and affecting about 0.5M to 4.1M American adults. Citing topline data from a pivotal Phase 3 trial, Vanda said Hetlioz reached the primary endpoint, shifting the sleep onset of patients with DSWPD by 42.5 minutes earlier compared with a 5.4-minute shift in those on placebo. There were no new safety signals, and the experimental therapy demonstrated a safety profile consistent with that of the established label of Hetlioz, according to the company. Available as capsules and an oral suspension, Hetlioz is already approved in the U.S. for adults with non-24-hour sleep-wake disorder and nighttime sleep disturbances due to Smith-Magenis Syndrome.

Vanda Pharmaceuticals announced that the European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion recommending orphan drug designation for Imsidolimab, its investigational monoclonal antibody, for the treatment of generalized pustular psoriasis. This marks the first time the EMA has formally recognized GPP as an orphan disease in Europe. The designation follows similar regulatory recognitions in the United States and Japan, and a Biologics License Application for Imsidolimab in GPP is currently under review by the FDA with a target action date of December 12, 2026. Vanda's CEO stated the positive opinion reinforces encouraging clinical data and highlights the urgent unmet medical need in GPP. The stock closed Thursday at $5.45, down 6.84%, but rose 4.19% to $5.68 in after-hours trading.

H.C. Wainwright reiterated a Buy rating on Vanda Pharmaceuticals with a price target of $21. The rating follows a Federal Register notice regarding Vanda's pursuit of FDA approval for HETLIOZ as a jet lag treatment. The FDA initially declined approval, but granted Vanda a formal evidentiary hearing—the first such hearing for any drug in over 40 years. A pre-hearing conference is set for July 20, 2026, with the actual hearing expected before year-end. The analyst noted that securing the jet lag indication could allow Vanda to generate branded prescription sales largely insulated from generic competition, despite existing generic tasimelteon on the market.

The global insomnia treatment market is projected to grow robustly through 2036, fueled by rising disease awareness and a pipeline of emerging therapies. In 2025, diagnosed prevalent cases of insomnia across the seven major markets—the United States, the EU4, the United Kingdom, and Japan—were estimated at approximately 90 million, with the United States accounting for the largest market share. Key pipeline candidates include Johnson & Johnson's Seltorexant, Vanda Pharmaceuticals' HETLIOZ, Idorsia's Daridorexant, and EUSOL Biotech's SM-1, which are expected to reshape the competitive landscape alongside recently approved orexin receptor antagonists such as VORZZZ in Japan. The market is also benefiting from the launch of novel drug classes like orexin antagonists and melatonin agonists, as well as increased adoption of cognitive behavioral therapy for insomnia.